biOasis Technologies makes siRNA breakthrough; InVivo Therapeutics Holdings details terms of IPO;

> Biomaterials company InVivo Therapeutics Holdings, focused on treating spinal cord injuries, announced the pricing and quantity of shares to be offered in its planned $14 million share offering. Release

> Central nervous system disease specialist biOasis Technologies says it has discovered a peptide vector that delivers siRNA into brain cells. Release

> The FDA approved Kinex Pharmaceuticals IND for an oral form of the cancer medication irinotecan. More

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.